--- title: "Viatris Inc. (VTRS.US)" type: "quote" locale: "en" url: "https://longbridge.com/en/quote/VTRS.US.md" symbol: "VTRS.US" name: "Viatris Inc." industry: "制药" --- # Viatris Inc. (VTRS.US) | Item | Detail | |------|--------| | Industry | 制药 | | Location | 美股市场 | | Website | [www.viatris.com](https://www.viatris.com) | ## Company Profile Viatris Inc.及其子公司在北美、欧洲、中国、台湾、香港、日本、澳大利亚、新西兰、其他亚洲地区、非洲、拉丁美洲和中东地区运营,作为一家医疗保健公司。它分为四个业务部门:发达市场、大中华区、JANZ 和新兴市场。该公司提供处方品牌药物、仿制药、复杂仿制药和生物类似药。它还提供涵盖多种非传染性和传染性疾病的各种治疗领域的药物,包括心血管、中央神经系统和麻醉、皮肤病、糖尿病和代谢、眼科、胃肠病学、免疫学、肿瘤学以及呼吸和过敏等,同时还提供支持服务,如诊断门诊、教育研讨会和数字工具,以帮助患者更好地管理他们的健康 ## Financial Score > *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.* > Updated: 2026-02-20T04:30:13.000Z **Overall: D (0.71)** **Industry**: Pharmaceuticals | Metric | Value | |--------|-------| | Industry Ranking | 126 / 190 | | Industry Median | C | | Industry Average | C | - **Style**: Value - Stocks where the company's main business is in a mature stage. - **Scale**: Large - The company has stable operations, allowing for dependable long-term returns. ### Score Analysis **Style Score**: #### Growth Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | -6.14% | | | Net Profit YoY | -317.90% | | #### Value Score: | Indicator | Value | Rating | |-----------|-------|--------| | P/B Ratio | 1.21 | | | Dividend Ratio | 3.00% | | **Size Score**: #### Market Cap Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 18.41B | | #### Revenue Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue | 14.12B | | **Multi Score**: D #### Profit Score: D | Indicator | Value | Rating | |-----------|-------|--------| | ROE | -21.09% | E | | Profit Margin | -26.13% | E | | Gross Margin | 39.84% | B | #### Growth Score: E | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | -6.14% | D | | Net Profit YoY | -317.90% | E | | Total Assets YoY | -15.27% | E | | Net Assets YoY | -23.11% | E | #### Cash Score: D | Indicator | Value | Rating | |-----------|-------|--------| | Cash Flow Margin | -382.64% | D | | OCF YoY | -6.14% | D | #### Operating Score: D | Indicator | Value | Rating | |-----------|-------|--------| | Turnover | 0.34 | D | #### Debt Score: D | Indicator | Value | Rating | |-----------|-------|--------| | Gearing Ratio | 59.87% | D | ```chart-data:radar { "title": "Longbridge Financial Score - Viatris Inc.", "chart_type": "radar", "dimensions": [ { "name": "Profit", "grade": "D", "indicators": [ { "name": "ROE", "value": "-21.09%", "rating": "E" }, { "name": "Profit Margin", "value": "-26.13%", "rating": "E" }, { "name": "Gross Margin", "value": "39.84%", "rating": "B" } ] }, { "name": "Growth", "grade": "E", "indicators": [ { "name": "Revenue YoY", "value": "-6.14%", "rating": "D" }, { "name": "Net Profit YoY", "value": "-317.90%", "rating": "E" }, { "name": "Total Assets YoY", "value": "-15.27%", "rating": "E" }, { "name": "Net Assets YoY", "value": "-23.11%", "rating": "E" } ] }, { "name": "Cash", "grade": "D", "indicators": [ { "name": "Cash Flow Margin", "value": "-382.64%", "rating": "D" }, { "name": "OCF YoY", "value": "-6.14%", "rating": "D" } ] }, { "name": "Operating", "grade": "D", "indicators": [ { "name": "Turnover", "value": "0.34", "rating": "D" } ] }, { "name": "Security", "grade": "D", "indicators": [ { "name": "Gearing Ratio", "value": "59.87%", "rating": "D" } ] } ] } ``` ### Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | |------|------|--------|--------|-----------|----------|------|--------| | 01 | 礼来 (US.LLY) | A | A | B | E | B | B | | 02 | ROCHE HOLDINGS AG (US.RHHVF) | A | B | B | D | C | B | | 03 | 罗氏(ADR) (US.RHHBY) | A | B | B | D | C | B | | 04 | 阿斯利康 (US.AZN) | A | B | C | D | C | B | | 05 | 诺华制药 (US.NVS) | A | B | C | D | C | B | ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | -4.99 | 157/257 | - | - | - | | PB | 1.21 | 57/257 | 0.85 | 0.73 | 0.63 | | PS (TTM) | 1.30 | 37/257 | 0.91 | 0.82 | 0.72 | | Dividend Yield | 3.00% | 11/257 | 5.45% | 4.85% | 4.19% | ## Institutional View ### Analyst Rating Distribution > As of 2026-02-11T05:00:00.000Z Total Analysts: **11** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 5 | 45% | | Overweight | 1 | 9% | | Hold | 4 | 36% | | Underweight | 1 | 9% | | Sell | 0 | 0% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 15.92 | | Highest Target | 16.00 | | Lowest Target | 10.00 | ## References - [Company Overview](https://longbridge.com/en/quote/VTRS.US/overview.md) - Shareholders, executives, business segments - [Financials](https://longbridge.com/en/quote/VTRS.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan - [Topics & Discussions](https://longbridge.com/en/quote/VTRS.US/topics.md) - Community topics and discussions --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.